Clinical Trials Logo

Rectal Cancer clinical trials

View clinical trials related to Rectal Cancer.

Filter by:

NCT ID: NCT06405308 Completed - Rectal Cancer Clinical Trials

Robotic Natural Orifice Specimen Extraction Surgery Versus Robotic Transabdominal Specimen Extraction Surgery for Early-Stage Rectal Cancer

Start date: October 1, 2023
Phase:
Study type: Observational

A retrospective cohort study, conducted nationwide(China) and across multiple centers, aimed to compare the surgical quality and short-term outcomes of R-NOSES (robotic natural orifice specimen extraction surgery)with R-TSES (robotic transabdominal specimen extraction surgery) for early-stage rectal cancer.

NCT ID: NCT06404554 Completed - Colorectal Cancer Clinical Trials

A Prediction Model of Anastomotic Stricture After Rectal Cancer

Start date: January 1, 2024
Phase:
Study type: Observational

Background: Anastomotic stricture significantly impacts patients' quality of life and long-term prognosis. However, current clinical practice lacks accurate tools for predicting anastomotic stricture. This study aimed to develop a nomogram to predict anastomotic stricture in patients with rectal cancer who have undergone anterior resection. Methods: 1542 eligible patients will be recruited for the study. Least absolute shrinkage selection operator (Lasso) analysis will be used to preliminarily select predictors. A prediction model will be constructed using multivariate logistic regression and presented as a nomogram. The performance of the nomogram will be evaluated using receiver operating characteristic (ROC) curves, calibration diagrams, and decision curve analysis (DCA). Internal validation will be conducted by assessing the model's performance on a validation cohort.

NCT ID: NCT06397053 Completed - Rectal Cancer Clinical Trials

Comparison of Robotic Versus Laparoscopic Surgery for Visceral Obesity in Mid-Low Rectal Cancer: A Propensity-Matched Analysis

Start date: December 1, 2019
Phase:
Study type: Observational

Our team has previously published articles providing detailed descriptions of the steps involved in both RS and LS. All surgeries adhered to the total mesorectal excision (TME) principle. In RS, a surgeon employed the Da Vinci Xi surgical system featuring a five-port setup, while five physicians conducted LS with a similarly configured five-port approach. Both the RS and LS doctors are experienced. The surgeries were conducted according to standard procedures, and the RS group utilized totally robotic rectal resection.

NCT ID: NCT06396975 Completed - Rectal Cancer Clinical Trials

Comparison of Short-term Outcomes of Robotic and Laparoscopic Surgery in Patients With Different Body Mass Index for Mid and Low Rectal Cancer

Start date: January 1, 2019
Phase:
Study type: Observational

Numerous comparison studies on the outcomes of robotic and laparoscopic surgery in the treatment of rectal cancer have been undertaken and reported. But there aren't many studies that compare the safety and effectiveness of the two surgery procedures used to treat people with mid and low rectal cancer who have different body mass indexes (BMIs). This study was done to organize the clinical data we had at our hospital so we could compare the perioperative effectiveness of two minimally invasive approaches for people with different BMIs.

NCT ID: NCT06395337 Not yet recruiting - Pancreatic Cancer Clinical Trials

Multimodal Imaging in Rectal Cancer & Pancreatic Cancer

MIRCA & MIPAC
Start date: May 2, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

Most digestive cancers show (over)expression of the tumour marker carcinoembryonic antigen (CEA). Therefore, interest in CEA-targeting tracers has increased over the past years. CEA-targeting tracers can be used for preoperative, intra-operative and postoperative imaging purposes. This study focusses on both preoperative and intraoperative multimodal imaging and image-guided surgery in patients with rectal cancer or pancreatic cancer.

NCT ID: NCT06391060 Completed - Rectal Cancer Clinical Trials

Gender Differences in Robotic Surgery for Rectal Cancer: a Retrospective Study

Start date: July 15, 2021
Phase:
Study type: Observational

Objective: To investigate gender-based differences in outcomes following robotic surgery for rectal cancer. Methods: A retrospective study was conducted on 155 patients (82 males, 73 females) who underwent robotic surgery for rectal cancer. Demographic, pre-operative, operative, and post-operative data were collected and analyzed. Pre-operative study: All patients underwent a standardized pre-operative work-up, which included a physical examination, comprehensive colonoscopy with biopsy, rigid rectoscopy, pelvic magnetic resonance imaging (MRI) scan, computed tomography (CT) of the thorax and abdomen, and measurement of carcinoembryonic antigen (CEA) levels. Tumor staging followed the TNM staging criteria (American Joint Committee on Cancer), with the T and N stages determined by the most advanced findings from any imaging modality Data collected: Retrospective evaluation and comparison of demographic characteristics, pre-operative TNM stage, distance from anal verge, tumor size, tumor grade, American Society of Anesthesiologists (ASA) score, and body mass index (BMI) were conducted among both patient groups. Peri-operative and post-operative data, including morbidity and mortality, were assessed, alongside parameters such as distal resection margin (DRM), proximal resection margin (PRM), harvested lymph nodes (HLN), and Clavien-Dindo Classification (CDC) scores. Diagnosis of anastomotic leakage was confirmed by clinical suspicion (e.g., changes in drainage, fever, abdominal pain) and further validated through contrast enema observed during follow-up computed tomography (CT). Hospital stay and readmission rates were monitored for up to 90 days post-surgery. Post-operative follow-up: Post-operative outcomes encompassed operative duration, estimated blood loss, time to first flatus passage, duration of liquid diet, and length of hospital stay following surgery. Operative duration comprised the time from initial skin incision to closure, including the time needed for robotic surgery docking and undocking. Upon experiencing initial flatulence, patients transitioned to a liquid diet. Hospital stay duration was measured from the time of surgery to discharge. The overall cost of surgery, including surgical procedures, anesthesia, medications, and post-operative care, was considered in the total expenditure analysis.

NCT ID: NCT06390982 Not yet recruiting - Rectal Cancer Clinical Trials

Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study

Start date: May 2024
Phase: Phase 2
Study type: Interventional

This is an open-label, multi-center, single-arm clinical study. All patients received concurrent chemoradiation therapy (CRT) followed by 4 cycles of tislelizumab combined with CAPOX, then underwent clinical response assessment. Patients who achieved CR (cCR+ pCR confirmed by local resection of ncCR) continue tislelizumab combined with CAPOX for another 4 cycles and tislelizumab for 9 cycles, then Watch and Wait. Patients who did not achieved CR underwent total mesorectal excision (TME).

NCT ID: NCT06382415 Completed - Rectal Cancer Clinical Trials

Organ/Space Surgical Site Infection and Recurrence and Survival in Rectal Cancer Surgery

VINCat_PDO_2
Start date: January 1, 2011
Phase:
Study type: Observational

In rectal cancer surgery, the organ/space surgical site infection (O/S-SSI) has an impact on patient's prognosis. Its influence in the oncologic outcomes remains controversial. The main objective is to assess the possible effect of O/S-SSI on long-term overall survival and cancer recurrence.

NCT ID: NCT06380855 Recruiting - Rectal Cancer Clinical Trials

Flexible Colonoscope Assisted Hybrid Transanal Total Mesorectal Resection (taTME)

Start date: August 24, 2022
Phase:
Study type: Observational

The investigators propose to use flexible endoscopy combined with transanal total mesorectal resection to further reduce anal injury.

NCT ID: NCT06380101 Recruiting - Rectal Cancer Clinical Trials

Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)

NEAAR-LARC
Start date: September 8, 2023
Phase: N/A
Study type: Interventional

This clinical study aims to assess feasibility, safety, tolerability, and compliance of a Nonessential Amino Acid Restriction (NEAAR) medical food in adult patients with locally advanced rectal cancer during standard of care short course radiotherapy followed by standard of care chemotherapy.